Nichi-Iko Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Second Quarter and Full Year of Fiscal Ending March 31, 2022
September 06, 2021 at 11:30 am IST
Nichi-Iko Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the second quarter and full year of fiscal ending March 31, 2022. For the second quarter, the company expects revenue of ¥94,000 million, Operating loss of ¥5,200 million, loss attributable to owners of parent of ¥5,300 million, Basic loss per share were ¥82.61.
For the year, the company expects revenue of ¥195,000 million, Operating profit of ¥500 million, Profit attributable to owners of parent of ¥200 million, Basic earnings per share of ¥3.12.